{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:36:48Z","timestamp":1761586608446,"version":"build-2065373602"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2012\/51692-7"],"award-info":[{"award-number":["2012\/51692-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ESR 14-10726"],"award-info":[{"award-number":["ESR 14-10726"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"INCT \/CNPq","award":["465259\/2014-6 and 303001\/2019-4"],"award-info":[{"award-number":["465259\/2014-6 and 303001\/2019-4"]}]},{"name":"INCT\/FAPESP","award":["14\/50983-3"],"award-info":[{"award-number":["14\/50983-3"]}]},{"name":"INCT\/CAPES","award":["88887.136373\/2017-00"],"award-info":[{"award-number":["88887.136373\/2017-00"]}]},{"DOI":"10.13039\/501100001807","name":"FAPESP","doi-asserted-by":"crossref","award":["2016\/24531-3"],"award-info":[{"award-number":["2016\/24531-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018861","name":"INCT-FCx","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018861","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ticagrelor has many protective cardiovascular properties beyond potent antiplatelet action. This study aimed to compare the effects of ticagrelor versus clopidogrel on infarcted mass, quantified by cardiac magnetic resonance (CMR), in patients with ST-segment elevation acute myocardial infarction (STEMI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients of both sexes with STEMI under a pharmaco-invasive strategy were included (n\u2009=\u2009225). Patients were treated by thrombolysis within six hours of symptom onset and underwent angiography with percutaneous coronary interventions, when needed, within the first 24 hours. Prior to the invasive procedures, patients were randomly assigned to receive either ticagrelor or clopidogrel using a centralized computerized system. Patients were followed on a weekly basis to optimize their medical therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After 30 days, CMR was performed and a smaller percentage of left ventricular infarcted mass was found with ticagrelor (p\u2009=\u20090.012), despite similar angiographic findings at baseline (Syntax score, Gensini score, culprit artery, TIMI flow, and myocardial blush). At 30 days, left ventricular ejection fraction (LVEF) was comparable between groups. Still, the K-means algorithm displayed more homogeneous responses for smaller infarcted mass and better LVEF among those patients treated with ticagrelor. Standard lipid panel and most inflammatory parameters were similar at baseline and after 30 days. However, lower high-sensitivity troponin T and high-sensitivity C-reactive protein levels were found in samples collected from patients treated with ticagrelor on the first day of STEMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with STEMI under a pharmaco-invasive strategy, therapy with ticagrelor was associated with a smaller infarct size than clopidogrel.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrials.gov (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02428374\" xlink:type=\"simple\">NCT02428374<\/jats:ext-link>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0328114","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:32:06Z","timestamp":1761586326000},"page":"e0328114","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Smaller infarct size with ticagrelor vs. clopidogrel in STEMI patients: Insights from cardiac magnetic resonance"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-4598","authenticated-orcid":true,"given":"Francisco A","family":"Fonseca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriano","family":"Caixeta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilberto","family":"Szarf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibraim","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6339-8699","authenticated-orcid":true,"given":"Antonio M","family":"Figueiredo Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina N","family":"Fran\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-8327","authenticated-orcid":true,"given":"Henrique T","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrique A","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda S","family":"Bacchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Birtche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-9913","authenticated-orcid":true,"given":"Igor R M","family":"Batista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5738-2623","authenticated-orcid":true,"given":"Maria C","family":"Izar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the BATTLE-AMI investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"11","key":"pone.0328114.ref001","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"L Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"pone.0328114.ref002","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ahj.2020.01.013","article-title":"Comparison between ticagrelor and clopidogrel on myocardial blood flow in patients with acute coronary syndrome, using 13 N-ammonia positron emission tomography","volume":"222","author":"YJ Jeong","year":"2020","journal-title":"Am Heart J"},{"issue":"10","key":"pone.0328114.ref003","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008105","article-title":"Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices","volume":"12","author":"K Park","year":"2019","journal-title":"Circ Cardiovasc Interv"},{"issue":"10233","key":"pone.0328114.ref004","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0140-6736(20)30325-1","article-title":"Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial","volume":"395","author":"M Gimbel","year":"2020","journal-title":"Lancet"},{"key":"pone.0328114.ref005","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.743259","article-title":"Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis","volume":"12","author":"X Zhao","year":"2021","journal-title":"Front Pharmacol"},{"key":"pone.0328114.ref006","doi-asserted-by":"crossref","first-page":"106828","DOI":"10.1016\/j.vph.2020.106828","article-title":"Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials","volume":"137","author":"M Verdoia","year":"2021","journal-title":"Vascul Pharmacol"},{"issue":"5","key":"pone.0328114.ref007","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention","volume":"9","author":"M Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"10439","key":"pone.0328114.ref008","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial","volume":"403","author":"Z Ge","year":"2024","journal-title":"The Lancet"},{"issue":"5","key":"pone.0328114.ref009","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamacardio.2018.0612","article-title":"Ticagrelor vs Clopidogrel After Fibrinolytic Therapy in Patients With ST-Elevation Myocardial Infarction: A Randomized Clinical Trial","volume":"3","author":"O Berwanger","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"22","key":"pone.0328114.ref010","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1016\/j.jacc.2019.03.011","article-title":"Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis","volume":"73","author":"O Berwanger","year":"2019","journal-title":"Journal of the American College of Cardiology"},{"issue":"25","key":"pone.0328114.ref011","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes","volume":"372","author":"CP Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"pone.0328114.ref012","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial","volume":"143","author":"GG Schwartz","year":"2021","journal-title":"Circulation"},{"issue":"21","key":"pone.0328114.ref013","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"PM Ridker","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0328114.ref014","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease","volume":"377","author":"PM Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"pone.0328114.ref015","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction","volume":"381","author":"J-C Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0328114.ref016","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"JL Mega","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"pone.0328114.ref017","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"MP Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0328114.ref018","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijcard.2021.10.138","article-title":"Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry","volume":"345","author":"A Cesaro","year":"2021","journal-title":"Int J Cardiol"},{"issue":"2","key":"pone.0328114.ref019","first-page":"129","article-title":"Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score","volume":"7","author":"R Klingenberg","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"14","key":"pone.0328114.ref020","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials","volume":"67","author":"GW Stone","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"pone.0328114.ref021","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1161\/CIRCULATIONAHA.114.009570","article-title":"ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up","volume":"130","author":"PR Sinnaeve","year":"2014","journal-title":"Circulation"},{"issue":"4","key":"pone.0328114.ref022","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.amjcard.2018.04.057","article-title":"Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction","volume":"122","author":"TJ Siddiqi","year":"2018","journal-title":"Am J Cardiol"},{"issue":"8","key":"pone.0328114.ref023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002049","article-title":"Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction?","volume":"4","author":"J Shavadia","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"pone.0328114.ref024","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1186\/s13063-017-2361-1","article-title":"Effects of four antiplatelet\/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial","volume":"18","author":"FAH Fonseca","year":"2017","journal-title":"Trials"},{"issue":"10","key":"pone.0328114.ref025","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000404","article-title":"2016 ACC\/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF\/AHA\/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF\/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease, 2013 ACCF\/AHA Guideline for the Management of ST-Elevation Myocardial Infarction, 2014 AHA\/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes, and 2014 ACC\/AHA Guideline on Perioperative Cardiovascular Evaluation and Management of Patients Undergoing Noncardiac Surgery","volume":"134","author":"GN Levine","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"pone.0328114.ref026","article-title":"Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction","volume":"41","author":"ACA Casarotti","year":"2021","journal-title":"Bioscience Reports"},{"key":"pone.0328114.ref027","article-title":"Altera\u00e7\u00f5es Precoces nas Interleucinas Circulantes e no Risco Inflamat\u00f3rio Residual ap\u00f3s Infarto Agudo do Mioc\u00e1rdio","author":"MER Coste","year":"2020","journal-title":"Arquivos Brasileiros de Cardiologia"},{"key":"pone.0328114.ref028","article-title":"Qualitative and Quantitative Coronary Angiography","volume-title":"Textbook of Interventional Cardiology","author":"c Topol E r i","year":"2020"},{"issue":"2","key":"pone.0328114.ref029","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12928-020-00653-7","article-title":"Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics","volume":"35","author":"N Suzuki","year":"2020","journal-title":"Cardiovasc Interv Ther"},{"issue":"14","key":"pone.0328114.ref030","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJM198504043121437","article-title":"The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings","volume":"312","author":"Group TIMI Study","year":"1985","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0328114.ref031","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1161\/01.CIR.93.5.879","article-title":"TIMI frame count: a quantitative method of assessing coronary artery flow","volume":"93","author":"CM Gibson","year":"1996","journal-title":"Circulation"},{"issue":"23","key":"pone.0328114.ref032","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1161\/01.CIR.97.23.2302","article-title":"Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group","volume":"97","author":"AW van \u2019t Hof","year":"1998","journal-title":"Circulation"},{"issue":"2","key":"pone.0328114.ref033","first-page":"219","article-title":"The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease","volume":"1","author":"G Sianos","year":"2005","journal-title":"EuroIntervention"},{"issue":"1","key":"pone.0328114.ref034","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","article-title":"Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update\u00a0: Society for Cardiovascular Magnetic Resonance (SCMR): Board of Trustees Task Force on Standardized Post-Processing","volume":"22","author":"J Schulz-Menger","year":"2020","journal-title":"J Cardiovasc Magn Reson"},{"issue":"3","key":"pone.0328114.ref035","article-title":"mice: Multivariate Imputation by Chained Equations inR","volume":"45","author":"van Buuren S","year":"2011","journal-title":"J Stat Soft"},{"issue":"2","key":"pone.0328114.ref036","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/heartjnl-2022-321868","article-title":"Effects of ticagrelor and prasugrel on coronary microcirculation in elective percutaneous coronary intervention","volume":"110","author":"F Mangiacapra","year":"2023","journal-title":"Heart"},{"issue":"1","key":"pone.0328114.ref037","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000491768","article-title":"Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: a Pilot Study","volume":"48","author":"C-Z Gao","year":"2018","journal-title":"Cell Physiol Biochem"},{"issue":"18","key":"pone.0328114.ref038","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial","volume":"327","author":"L R\u00e4ber","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"pone.0328114.ref039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273292","article-title":"Changes in lipoproteins associated with lipid-lowering and antiplatelet strategies in patients with acute myocardial infarction","volume":"17","author":"Z Lotfollahi","year":"2022","journal-title":"PLoS ONE"},{"issue":"3","key":"pone.0328114.ref040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/bmjebm-2023-112476","article-title":"De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis","volume":"29","author":"O De Filippo","year":"2024","journal-title":"BMJ Evid Based Med"},{"issue":"10456","key":"pone.0328114.ref041","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials","volume":"404","author":"M Valgimigli","year":"2024","journal-title":"Lancet"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:32:15Z","timestamp":1761586335000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328114"}},"subtitle":[],"editor":[{"given":"Shukri","family":"AlSaif","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328114","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2025,10,27]]}}}